Uroplasty Appoints New R&D Executive

Uroplasty Inc. has appointed Suranjan Roychowdhury, Ph.D., as vice president of Research & Development and Clinical Affairs. The newly created position within the company was established to provide focus, oversight and guidance to the firm’s product pipeline and clinical trials. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices.

“This new position adds an important element to our strategic direction and product development capabilities. Suranjan’s highly relevant background and depth of experience will enable him to immediately add value and provide direction to our R&D initiatives, as well as lead our clinical programs,” said Rob Kill, president & CEO.

Roychowdhury served for more than eight years in advancing executive roles with American Medical Systems Inc., including leadership of R&D as well as the clinical, regulatory, and healthcare economics functions for the $230 million Men’s Health division. Most recently, Roychowdhury was with Vascular Solutions Inc., a Minneapolis, Minn.-based cardiovascular medical device company. He also has served in executive roles with Sulzer Spine-Tech (now Zimmer Spine), Boston Scientific Corp., and Schneider USA (Pfizer).

Roychowdhury holds a B.Tech in metallurgical engineering from the Indian Institute of Technology at Varanasi, and M.S. and Ph.D. degrees in materials science and engineering from the University of Delaware. He is the author of several publications on urology and cardiovascular topics. In addition, he holds 20 issued U.S. patents for medical devices in cardiology, orthopedics,
urology and drug delivery.

Overactive bladder is a chronic condition that affects approximately 41 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. The Urgent PC Neuromodulation System is the only U.S. Food and Drug Administration (FDA)-cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.

Headquartered in Minnetonka, Minn., with wholly-owned subsidiaries in The Netherlands and the United Kingdom, Uroplasty develops, manufactures and markets products to treat voiding dysfunctions and pelvic disorders. The company developed both the Urgent PC Neuromodulation System, an FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence, and Macroplastique, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.